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Supplementary Figure 1. Related to Figure 1. a. Number of fusions detected per sample, stratified by hyperdiploid sta-
tus. b. Fusion caller overlap after filtering. Source data and scripts are available at doi.org/10.6084/m9.figshare.11941494.
PFS ~ ISS + Age + WHSC1 fusion
# Events: 364; Global p−value (Log−Rank): 5.7613e−09 
































# Events: 364; Global p−value (Log−Rank): 6.1594e−09 
AIC: 4212.49; Concordance Index: 0.6































# Events: 364; Global p−value (Log−Rank): 9.4689e−10 
AIC: 4208.58; Concordance Index: 0.6
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# Events: 364; Global p−value (Log−Rank): 7.6926e−09 
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# Events: 43; Global p−value (Log−Rank): 0.034825 
AIC: 300.27; Concordance Index: 0.66
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PFS ~ ISS + Age + FGFR3 Mutation + FGFR3 Expression
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# Events: 289; Global p−value (Log−Rank): 2.875e−09 
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Supplementary Figure 2. Related to Figures 1, 5, 6. a-f. Progression-free survival (PFS) models using multivariate Cox 
proportional hazards. Error bars indicate a 95% confidence interval on each hazard ratio estimate. Covariate p-values 
derived from z-scores are two-sided. Source data and scripts are available at doi.org/10.6084/m9.figshare.11941494.
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Supplementary Figure 3. Related to Figure 3. Expression percentile of cancer-related genes (marked with *) in patients 
with samples from multiple clinic visits or tissue sites (bone marrow, BM, or peripheral blood, PB). Tumor purity of PB 

























































































































































Supplementary Figure 4. Related to Figure 4. a-b. Cell types and Fuscia scRNA-seq fusion discovery for Patient 
27522 (primary, relapse) with t(4;14). Results from overlapping and non-overlapping regions. c-d. Patient 56203 (pri-
mary, relapse) with t(8;14). e. Patient 47499 (CD138+ sorted primary) with t(11;14). f. Patient 77570 (primary) with 
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Supplementary Figure 5. Related to Figure 4. a. Single cell expression of WHSC1. b. Single cell expression of FGFR3. 
c. Mapping location and number of ‘Chimeric Transcripts’ linking IGH with various ‘Partner’ genes which do not form real 
fusions with IGH except for WHSC1. Source data and scripts are available at doi.org/10.6084/m9.figshare.11941494.
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Supplementary Figure 6. Related to Figure 5. a. Breakpoint mapping locations at IGH and WHSC1, split by FGFR3 
expression. b. WHSC1 and FGFR3 copy number in samples with IGH fusion. c. Breakpoint (BP) mapping location at 
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Supplementary Figure 7. Related to Figure 6. Fusion breakpoint mapping locations at Ig loci, MYC, and PVT1. Source 
data and scripts are available at doi.org/10.6084/m9.figshare.11941494.
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Supplementary Figure 8. a. Overlap of fusion calls with DEPO drug target database. b. Cancer types with exact fusion 
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Supplementary Figure 9. a. MMRF 3’ intact kinase fusion partner genes overlapping with TCGA cancer types (number of 
samples). b. MMRF NTRK1 partner genes overlapping with TCGA cancer types. Source data and scripts are available at 
doi.org/10.6084/m9.figshare.11941494.
